RESULTS	Among high-body-weight subjects , adverse events ( AEs ) were reported by 57.1 % of subjects in both the high - and low-dose varenicline groups and by 14.3 % of subjects in the placebo group ; among low-body-weight subjects , AEs were reported by 64.3 % , 73.3 % , and 12.5 % of subjects in the high-dose varenicline , low-dose varenicline , and placebo groups , respectively .\